ASH® 2025 Highlights: Presenter Vignette – Dennis Kim
Dennis Kim
MD, PhD
Princess Margaret Cancer Centre
4284
Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD
This program has been made possible through unrestricted support from Astellas, Daiichi Sankyo, Eli Lilly and Merck.
